New drugs for chronic hepatitis B: A review

American Journal of Therapeutics

Volumn 15, Issue 2, 2008, Pages 167-172

  Palumbo, Emilio ^a,b  

^a Hospital of Sondrio   (Italy)

^b NONE   (Italy)

Author keywords

Clevudine; Emtricitabine; Entecavir; Hepatitis B; Pharmacokinetics; Pharmacology; Telbivudine

Indexed keywords

ADEFOVIR DIPIVOXIL; CLEVUDINE; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; PLACEBO; PROBENECID; TELBIVUDINE;

ANTIVIRAL ACTIVITY; CHRONIC DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DNA DETERMINATION; DNA REPLICATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS B; HUMAN; IN VITRO STUDY; KIDNEY INJURY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ADENINE; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; DEOXYCYTIDINE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; NUCLEOSIDES; PHOSPHONIC ACIDS; PYRIMIDINONES;

EID: 41349105992     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e318155a191     Document Type: Review

References (22)

1. Chu CM, Liau YF. Natural history of chronic B virus infection: an immunopathological study. J Gastroenterol Hepatol. 1997;12:S218-S222.
2. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med. 2004;350:1118-1129.
3. Olivero F, Santantonio T, Bellati G, et al. Long-term response to therapy of chronic anti-Hbe-positive hepatitis B is poor independent of type and schedule of interferon. Am J Gastroenterol. 1999;94:1366-1372.
4. van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology. 2004;39:804-810.
5. Lai CL, Chien RN, Leung NW, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med. 1998;339:61-68.
6. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341:1256-1263.
7. Lau DT, Khokhar F, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology. 2000;32:828-834.
8. Zeng M, Mao Y, Yao G, et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology. 2006;44:108-116.
9. Hadziyannis SJ, Tassopoulos N, Heathcote EJ, et al. Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348:800-807.
10. Yan JH, Bifano M, Olsen S, et al. Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. J Clin Pharmacol. 2006;46:1250-1258.
11. Hadziyannis SJ. New developments in the treatment of chronic hepatitis B. Exp Opin Biol Ther. 2006;6:913-921.
12. Zhou XX, Littler E. Nucleoside analogs as anti-HBV agents. Curr Top Med Chem. 2006;6:851-865.
13. Dienstag JL. Looking to the future: new agents for chronic hepatitis B. Am J Gastroenterol. 2006,101(Suppl 1):S19-25.
14. Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology. 2002;123:1831-1838.
15. Sherman M, Yurdayin C, Sollano J, et al. AI463026 Behold Study Group. Entecavir for treatment of lamivudinerefractory HBeAg-positive chronic hepatitis B. Gastroenterology. 2006;130:2039-2049.
16. Lai CL, Shouval D, Lok AS, et al. AI463027 Behold Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011-1020.
17. Chang TT, Gish RG, de Mau R, et al. AI463022 Behold Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001-1010.
18. Chang TT, Gish RG, Hadziyannis SJ, et al. Behold Study Group. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory clinic hepatitis B patients. Gastroenterology. 2005;129:1198-1209.
19. Leung N, Gish RG, Wanf C, et al. A randomized, double-blind comparison of 3 doses of emtricitabine in patients with chronic hepatitis B given 48 weeks of treatment. Hepatology. 2001;34:349A.
20. Lai CL, Leung N, Teo EK, et al. Telbivudine Phase II Investigator Group. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005;129:528-536.
21. Marcellin P, Monmeia-Marin H, Sacks SL, et al. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology. 2004;40:140-148.
22. Lee HS, Chung YH, Lee K, et al. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology. 2006;43:982-988.